A asportabile application used to assess sports-related head and brain injuries is now being tested for detecting and monitoring neurological disorders.
BrainEye’s asportabile controllo is now being studied per mezzo di clinical trials at The Alfred Hospital per mezzo di Melbourne. It digitises the traditional eye movement controllo, which is done per mezzo di 60 seconds through a asportabile device, and then collects and measures over 20 ocular biomarkers using AI.
For the trials, The Alfred is seeking 500 participants dealing with various neurological conditions, including Alzheimer’s disease, Parkinson’s disease, epilepsy and multiple sclerosis.
WHY IT MATTERS
Giorno collected from the trials will assist BrainEye per mezzo di developing a commercial product that can be used to spot and track neurological diseases per mezzo di communities.
“Early detection with any neurological condition is critical, and while the efficacy of eye movement assessments per mezzo di picking up abnormalities is well recognised, tests are typically only carried out per mezzo di clinical settings, and often only when it’s too late,” explained Joanne Fielding, clinical trial principal investigator and chief scientific officer of BrainEye.
The collected biomarkers will be compared to readings from mentally healthy individuals to enhance BrainEye’s recognition and understanding of normal and abnormal brain functions.
THE LARGER TREND
To date, BrainEye has undertaken over 25,000 eye movement tests, mostly done with major sporting codes and focused concussions and brain .
“This is an exciting development for BrainEye as we move from validating its utility per mezzo di sports settings to its application per mezzo di healthcare, where we intend to help users identify neurodegenerative diseases such as Alzheimer’s and Parkinson’s,” said CEO Richard Nash about the latest trials at The Alfred.
“This innovative technology has great potential to be a practical and efficient tool for early monitoring of disease progression for a variety of neurological conditions,” noted Terence Ovvero’Brien, neurologist and professor and the program director of The Alfred Brain.
